As a proponent of viewing depression as a "psychohobiological", dimensional disorder, and the antidepressants as having multiple clinical actions associated with differential impact on its neurobehavioral components, I realize that a number of technical and methodological concerns are raised in my book about how research is conducted on these issues. Don Klein is aware of these issues and their application to clinical research, generally. He apparently plans to identify them and to open them for discussion. I look forward to a useful interchange on these matters and trust that other members of the Network will participate in the discussion.
Martin M. Katz
February 13, 2014